AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition


AbbVie is acquiring Landos Biopharma for $20.42 per share, a 155% premium, to expand its scope in treating ulcerative colitis. Landos’s drug, NX-13, targets the NLRX1 receptor associated with inflammatory disorders in the gut. In Phase 1b trials, NX-13 showed safety and clinical improvement in patients with ulcerative colitis. A Phase 2 trial is ongoing. AbbVie’s pipeline includes drugs like Humira, Rinvoq, and Skyrizi for treating inflammatory bowel disorders. The acquisition also includes a contingent value right tied to a clinical development milestone. Analysts believe the acquisition is a strategic fit for AbbVie with minimal risks.

Source link

error: Content is protected !!